Translate

2017 Information Womens Health Cluster Drug Development Pipeline Review, 2017

"Womens Health Cluster Drug Development Pipeline Review, 2017" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.

Description-

This report provides an overview of the women’s health pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for female infertility, polycystic ovarian syndrome and endometriosis, and also features dormant and discontinued projects.


The three key disorders covered in this report are largely driven by dysfunction of the endocrine system, but have a broad range of effects. Infertility is defined as the inability to get pregnant after a year of unprotected intercourse. Female infertility can be also be caused by a number of factors, which include damage to fallopian tubes, hormonal causes, cervical causes, uterine causes, unexplained infertility. Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. Finally, endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (the endometrium) grows outside the uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding.
The size of these pipelines ranges from 12 in PCOS to 87 in female infertility. The most common types of therapy being developed in these diseases act on hormone receptors, reflecting the hormone-driven pathophysiology of this disease area. However, particularly in polycystic ovarian syndrome, a broader range of molecular targets, such as intracellular protein kinases, chemokine receptors and other cell signaling components are also targeted.
Scope
  • Which companies are the most active within the pipeline for women’s health therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of women’s health therapeutics?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

GBI Research Report Guidance 2

Executive Summary 3
Table of Contents 4
List of Tables 5
List of Figures 8
Introduction 9
Women's Health Cluster Report Coverage 9
Women Infertility – Overview 9
Polycystic Ovarian Syndrome – Overview 9
Endometriosis – Overview 9
Therapeutics Development 10
Women Infertility 10
Polycystic Ovarian Syndrome 18
Endometriosis 22
Therapeutics Assessment 29
Women Infertility 29
Polycystic Ovarian Syndrome 37
Endometriosis 45
Companies Involved in Therapeutics Development 53
Women Infertility 53
Polycystic Ovarian Syndrome 74
Endometriosis 77
Dormant Projects 89
Women Infertility 89
Polycystic Ovarian Syndrome 91
Endometriosis 92
Discontinued Products 93
Women Infertility 93
Polycystic Ovarian Syndrome 93
Endometriosis 94
Product Development Milestones 95
Women Infertility 95
Polycystic Ovarian Syndrome 105
Endometriosis 112
Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 123
Disclaimer 123

List of Table

Number of Products under Development for Women Infertility 10
Number of Products under Development by Companies, Women Infertility 11
Number of Products under Development by Universities/Institutes, Women Infertility 13
Products under Development by Companies, Women Infertility 14
Products under Development by Universities/Institutes, Women Infertility 17
Number of Products under Development for Polycystic Ovarian Syndrome 18
Number of Products under Development by Companies, Polycystic Ovarian Syndrome 19
Number of Products under Development by Universities/Institutes, Polycystic Ovarian Syndrome 20
Products under Development by Companies, Polycystic Ovarian Syndrome 21
Products under Development by Universities/Institutes, Polycystic Ovarian Syndrome 21
Number of Products under Development for Endometriosis 22
Number of Products under Development by Companies, Endometriosis 24
Number of Products under Development by Universities/Institutes, Endometriosis 25
Products under Development by Companies, Endometriosis 26
Products under Development by Universities/Institutes, Endometriosis 28
Number of Products by Stage and Target, Women Infertility 30
Number of Products by Stage and Mechanism of Action, Women Infertility 32
Number of Products by Stage and Route of Administration, Women Infertility 34
Number of Products by Stage and Molecule Type, Women Infertility 36
Number of Products by Stage and Target, Polycystic Ovarian Syndrome 38
Number of Products by Stage and Mechanism of Action, Polycystic Ovarian Syndrome 40
Number of Products by Stage and Route of Administration, Polycystic Ovarian Syndrome 42
Number of Products by Stage and Molecule Type, Polycystic Ovarian Syndrome 44
Number of Products by Stage and Target, Endometriosis 46
Number of Products by Stage and Mechanism of Action, Endometriosis 48
Number of Products by Stage and Route of Administration, Endometriosis 50
Number of Products by Stage and Molecule Type, Endometriosis 52
Women Infertility – Pipeline by 4P Therapeutics LLC 53



Comments

Post a Comment